BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Søreide K. Proteinase-activated receptor 2 (PAR-2) in gastrointestinal and pancreatic pathophysiology, inflammation and neoplasia. Scand J Gastroenterol 2008;43:902-9. [PMID: 19086162 DOI: 10.1080/00365520801942141] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Cai T, Wang X, Li B, Xiong F, Wu H, Yang X. Deciphering the synergistic network regulation of active components from SiNiSan against irritable bowel syndrome via a comprehensive strategy: Combined effects of synephrine, paeoniflorin and naringin. Phytomedicine 2021;86:153527. [PMID: 33845366 DOI: 10.1016/j.phymed.2021.153527] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Hait EJ, McDonald DR. Impact of Gastroesophageal Reflux Disease on Mucosal Immunity and Atopic Disorders. Clin Rev Allergy Immunol 2019;57:213-25. [PMID: 30206783 DOI: 10.1007/s12016-018-8701-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
3 Søreide K, Roalsø M, Aunan JR. Is There a Trojan Horse to Aggressive Pancreatic Cancer Biology? A Review of the Trypsin-PAR2 Axis to Proliferation, Early Invasion, and Metastasis. J Pancreat Cancer 2020;6:12-20. [PMID: 32064449 DOI: 10.1089/pancan.2019.0014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
4 Mukherjee S, Joardar N, Sengupta S, Sinha Babu SP. Gut microbes as future therapeutics in treating inflammatory and infectious diseases: Lessons from recent findings. J Nutr Biochem 2018;61:111-28. [PMID: 30196243 DOI: 10.1016/j.jnutbio.2018.07.010] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 7.6] [Reference Citation Analysis]
5 Sarojini S. Gut Microbes: The Miniscule Laborers in the Human Body. Diet, Microbiome and Health 2018. [DOI: 10.1016/b978-0-12-811440-7.00001-6] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
6 Bergemalm D, Kruse R, Sapnara M, Halfvarson J, Hörnquist EH. Elevated fecal peptidase D at onset of colitis in Galphai2-/- mice, a mouse model of IBD. PLoS One 2017;12:e0174275. [PMID: 28323866 DOI: 10.1371/journal.pone.0174275] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
7 Tillu DV, Hassler SN, Burgos-Vega CC, Quinn TL, Sorge RE, Dussor G, Boitano S, Vagner J, Price TJ. Protease-activated receptor 2 activation is sufficient to induce the transition to a chronic pain state. Pain 2015;156:859-67. [PMID: 25734998 DOI: 10.1097/j.pain.0000000000000125] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 5.3] [Reference Citation Analysis]
8 Hullar MA, Burnett-Hartman AN, Lampe JW. Gut microbes, diet, and cancer. Cancer Treat Res 2014;159:377-99. [PMID: 24114492 DOI: 10.1007/978-3-642-38007-5_22] [Cited by in Crossref: 78] [Cited by in F6Publishing: 84] [Article Influence: 8.7] [Reference Citation Analysis]
9 Michael ES, Kuliopulos A, Covic L, Steer ML, Perides G. Pharmacological inhibition of PAR2 with the pepducin P2pal-18S protects mice against acute experimental biliary pancreatitis. Am J Physiol Gastrointest Liver Physiol 2013;304:G516-26. [PMID: 23275617 DOI: 10.1152/ajpgi.00296.2012] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
10 Kandulski A, Malfertheiner P. Gastroesophageal reflux disease--from reflux episodes to mucosal inflammation. Nat Rev Gastroenterol Hepatol 2011;9:15-22. [PMID: 22105108 DOI: 10.1038/nrgastro.2011.210] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 3.8] [Reference Citation Analysis]
11 Boitano S, Flynn AN, Schulz SM, Hoffman J, Price TJ, Vagner J. Potent agonists of the protease activated receptor 2 (PAR2). J Med Chem 2011;54:1308-13. [PMID: 21294569 DOI: 10.1021/jm1013049] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
12 Søreide K. Impact of Microbial Infections on the Human Epigenome and Carcinogenesis. Handbook of Epigenetics 2011. [DOI: 10.1016/b978-0-12-375709-8.00029-0] [Reference Citation Analysis]
13 Souza RF. Bringing GERD Management up to PAR-2. Am J Gastroenterol 2010;105:1944-6. [PMID: 20818348 DOI: 10.1038/ajg.2010.272] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
14 Gaber A, Johansson M, Stenman UH, Hotakainen K, Pontén F, Glimelius B, Bjartell A, Jirström K, Birgisson H. High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer. Br J Cancer 2009;100:1540-8. [PMID: 19384300 DOI: 10.1038/sj.bjc.6605047] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 3.9] [Reference Citation Analysis]
15 Søreide K, Nedrebø BS, Knapp J, Glomsaker TB, Søreide JA, Kørner H. Evolving molecular classification by genomic and proteomic biomarkers in colorectal cancer: Potential implications for the surgical oncologist. Surgical Oncology 2009;18:31-50. [DOI: 10.1016/j.suronc.2008.06.006] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
16 Solberg A, Holmdahl L, Falk P, Willén R, Palmgren I, Ivarsson ML. Progress of tissue injury in appendicitis involves the serine proteases uPA and PAI-1. Scand J Gastroenterol 2009;44:579-84. [PMID: 19153874 DOI: 10.1080/00365520802699286] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
17 Waldum HL. August issue of Scandinavian Journal of Gastroenterology. Scand J Gastroenterol 2008;43:899-901. [PMID: 18649223 DOI: 10.1080/00365520802273348] [Reference Citation Analysis]